理邦儀器(300206.SZ):2019年淨利升42.30%至1.32億元 擬10派1.72元
格隆匯4月27日丨理邦儀器(300206.SZ)披露2019年年度報告,報告期內,公司實現營業收入11.36億元,同比增長14.46%;歸屬於上市公司股東的淨利潤1.32億元,同比增長42.30%;歸屬於上市公司股東的扣除非經常性損益的淨利潤1.15億元,同比增長197.60%;經營活動現金淨流入1.15億元,同比增長40.02%;基本每股收益0.2261元,年報推10派1.72元(含税)。
公司的傳統產品線包含病人監護系列、婦幼健康系列、心電診斷系列,均處於國內公司中第一梯隊。除此之外,公司產品還包含超聲影像系列和體外診斷系列。超聲影像系列由美國硅谷研發團隊和深圳超聲研發團隊共同研發,具有高性價比,基於穩定的系統平台和前沿的超聲技術,能夠提供具有説服力的清晰圖像,實現快速、可靠的診斷。體外診斷產品線運用了智能微流控、生物芯片等前沿科技創新技術,推出的i15血氣生化分析儀、m16及m36X磁敏免疫分析儀均處於國際領先水平。
2019年10月,公司通過旗下全資子公司理邦診斷完成了對 LGC Limited的快速診斷(POCT)ClariLight分子診斷平台業務的收購,同時還與LGC建立了戰略合作關係,雙方將共同開發基於ClariLight平台的分子診斷試劑,以及提供試劑生產所需的酶和寡核苷酸等原材料,預計新品可在未來兩年內上市,公司體外診斷產品線進一步得到豐富。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.